tiprankstipranks
Blueprint Medicines (BPMC)
NASDAQ:BPMC
US Market
Holding BPMC?
Track your performance easily

Blueprint Medicines (BPMC) Stock Forecast & Price Target

553 Followers
See the Price Targets and Ratings of:

BPMC Analyst Ratings

Moderate Buy
14Ratings
9 Buy
5 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Blueprint
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BPMC Stock 12 Month Forecast

Average Price Target

$122.92
▲(18.25% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $122.92 with a high forecast of $155.00 and a low forecast of $88.00. The average price target represents a 18.25% change from the last price of $103.95.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"71":"$71","156":"$156","92.25":"$92.3","113.5":"$113.5","134.75":"$134.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$155.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":122.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$122.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$88.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[71,92.25,113.5,134.75,156],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.22,92.43384615384615,97.64769230769231,102.86153846153846,108.07538461538462,113.28923076923077,118.50307692307692,123.71692307692308,128.93076923076922,134.14461538461538,139.35846153846154,144.57230769230767,149.78615384615384,{"y":155,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.22,89.96615384615384,92.71230769230769,95.45846153846153,98.20461538461538,100.95076923076923,103.69692307692307,106.44307692307692,109.18923076923076,111.9353846153846,114.68153846153845,117.42769230769231,120.17384615384616,{"y":122.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.22,87.28,87.34,87.4,87.46,87.52,87.58,87.64,87.7,87.76,87.82,87.88,87.94,{"y":88,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":72.05,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.07,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.88,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.42,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.86,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.56,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.18,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.54,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.62,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$155.00Average Price Target$122.92Lowest Price Target$88.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan
Buy
Reiterated
01/06/25
J.P. Morgan Sticks to Its Buy Rating for Blueprint Medicines (BPMC)
H.C. Wainwright
$135
Buy
29.87%
Upside
Reiterated
11/15/24
Blueprint Medicines: Innovative Approaches and Pipeline Potential Drive Buy Rating
Oppenheimer
$130
Buy
25.06%
Upside
Reiterated
10/30/24
Blueprint management moves maybe made with buyer in mind, says OppenheimerBlueprint management moves maybe made with buyer in mind, says Oppenheimer
UBS
$88
Hold
-15.34%
Downside
Initiated
10/24/24
Blueprint Medicines initiated with a Neutral at UBSBlueprint Medicines initiated with a Neutral at UBS
Goldman Sachs
Buy
Reiterated
08/01/24
Blueprint Medicines: A Strong Buy on Ayvakit's Success and Promising Pipeline

Best Analysts Covering Blueprint Medicines

Which Analyst Should I Follow If I Want to Buy BPMC and Sell After:
1 Month
xxx
Success Rate
11/16 ratings generated profit
69%
Average Return
+2.48%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 68.75% of your transactions generating a profit, with an average return of +2.48% per trade.
3 Months
xxx
Success Rate
13/22 ratings generated profit
59%
Average Return
+6.00%
assigned a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +6.00% per trade.
1 Year
Ami FadiaNeedham
Success Rate
12/15 ratings generated profit
80%
Average Return
+39.99%
reiterated a buy rating 5 days ago
Copying Ami Fadia's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +39.99% per trade.
2 Years
xxx
Success Rate
20/22 ratings generated profit
91%
Average Return
+47.42%
assigned a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +47.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BPMC Analyst Recommendation Trends

Rating
Sep 24
Oct 24
Nov 24
Dec 24
Jan 25
Strong Buy
5
9
8
6
3
Buy
10
12
7
8
10
Hold
6
10
9
10
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
31
24
24
21
In the current month, BPMC has received 13 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. BPMC average Analyst price target in the past 3 months is $122.92.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BPMC Financial Forecast

BPMC Earnings Forecast

Next quarter’s earnings estimate for BPMC is -$0.69 with a range of -$0.96 to -$0.48. The previous quarter’s EPS was -$0.89. BPMC beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 55.77% of the time in the same period. In the last calendar year BPMC has Outperformed its overall industry.
Next quarter’s earnings estimate for BPMC is -$0.69 with a range of -$0.96 to -$0.48. The previous quarter’s EPS was -$0.89. BPMC beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 55.77% of the time in the same period. In the last calendar year BPMC has Outperformed its overall industry.

BPMC Sales Forecast

Next quarter’s sales forecast for BPMC is $146.32M with a range of $141.00M to $161.45M. The previous quarter’s sales results were $128.18M. BPMC beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.15% of the time in the same period. In the last calendar year BPMC has Outperformed its overall industry.
Next quarter’s sales forecast for BPMC is $146.32M with a range of $141.00M to $161.45M. The previous quarter’s sales results were $128.18M. BPMC beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.15% of the time in the same period. In the last calendar year BPMC has Outperformed its overall industry.

BPMC Stock Forecast FAQ

What is BPMC’s average 12-month price target, according to analysts?
Based on analyst ratings, Blueprint Medicines’s 12-month average price target is $122.92.
    What is BPMC’s upside potential, based on the analysts’ average price target?
    Blueprint Medicines has 18.25% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BPMC a Buy, Sell or Hold?
          Blueprint Medicines has a consensus rating of Moderate Buy which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Blueprint Medicines’s price target?
            The average price target for Blueprint Medicines is $122.92. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $155.00 ,the lowest forecast is $88.00. The average price target represents 18.25% Increase from the current price of $103.95.
              What do analysts say about Blueprint Medicines?
              Blueprint Medicines’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of BPMC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis